2025
Factors influencing the decision to discontinue treatment due to chemotherapy-induced peripheral neuropathy among patients with metastatic breast cancer: a best–worst scaling
Radwan R, Bridges J, Hertz D, Lustberg M, Vachhani H, Hickey Zacholski E, Sheppard V, Salgado T. Factors influencing the decision to discontinue treatment due to chemotherapy-induced peripheral neuropathy among patients with metastatic breast cancer: a best–worst scaling. Supportive Care In Cancer 2025, 33: 467. PMID: 40347310, PMCID: PMC12065726, DOI: 10.1007/s00520-025-09508-4.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyMetastatic breast cancerRisk of treatment discontinuationLong-term neuropathyCancer treatment optionsTreatment discontinuationTreatment optionsPeripheral neuropathyBreast cancerReduced riskNeuropathy symptomsBest-worst scalingNeurotoxic chemotherapyTherapeutic outcomesLoved onesNeuropathyPatientsCancerResultsThe sampleMethodsAn online surveyWomenScoresConclusionWhenRiskChemotherapyClinical Utility of Anorectal Manometry in Children with Functional Constipation: Can Anorectal Manometry Help Predict the Therapeutic Response?
Patel D, Decker C, Rodriguez L. Clinical Utility of Anorectal Manometry in Children with Functional Constipation: Can Anorectal Manometry Help Predict the Therapeutic Response? Children 2025, 12: 512. PMID: 40310128, PMCID: PMC12025627, DOI: 10.3390/children12040512.Peer-Reviewed Original ResearchRecto-anal inhibitory reflexAnorectal manometryTherapeutic responsePredicting therapeutic responseFunctional constipationPediatric patientsRectal sensationSurgical interventionAssociated with better therapeutic outcomesTherapeutic response rateAnal resting pressureRetrospective chart reviewAnorectal manometry parametersEventual needAge-appropriate patientsBowel movement frequencyDyssynergic defecationTertiary centerTargeted therapyPediatric GastroenterologyFecal incontinenceStimulant laxativesChart reviewInhibitory reflexTherapeutic outcomesMIF as an oncogenic driver of low‐heterogeneity melanomas
Tran T, Sánchez‐Zuno G, Kulkarni R, Kluger H, Bucala R. MIF as an oncogenic driver of low‐heterogeneity melanomas. Molecular Oncology 2025, 19: 1295-1298. PMID: 40131169, PMCID: PMC12077282, DOI: 10.1002/1878-0261.70031.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorImproving therapeutic outcomesMigration inhibitory factorPotential therapeutic utilityImmune landscapeMelanoma clonesImmune escapeT cellsImmunoregulatory cytokinesTumor heterogeneityTumor progressionOncogenic driversPathway inhibitorTherapeutic outcomesTumor evolutionInhibitory factorCell proliferationMelanomaTumorCellsAntagonistCytokinesExploring Calcium Channels as Potential Therapeutic Targets in Blast Traumatic Brain Injury
Wachtler N, O’Brien R, Ehrlich B, McGuone D. Exploring Calcium Channels as Potential Therapeutic Targets in Blast Traumatic Brain Injury. Pharmaceuticals 2025, 18: 223. PMID: 40006037, PMCID: PMC11859800, DOI: 10.3390/ph18020223.Peer-Reviewed Original ResearchCalcium signalingCalcium channelsTherapeutic strategiesCalcium homeostasisFunction of calcium channelsDysregulated calcium signalingModulation of injuryTraumatic brain injuryBrain injuryLoss of calcium homeostasisBlast-related traumatic brain injuryDevelopment of neuroprotective interventionsIntracellular calcium dynamicsPlasma membrane stabilityExtracellular calciumBlast traumatic brain injuryPreclinical modelsTherapeutic outcomesNeuroprotective interventionsMembrane abnormalitiesPharmacological inhibitorsNeuronal somataExclusion criteriaCalcium dynamicsSecondary injury
2024
Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
Braunstein Z, McLaughlin E, Lingamaneni P, Barta S, Cao M, Chang T, Ganesan N, Luu B, Mehta-Shah N, Shree T, Watkins M, Zain J, Allen P, Paulino D, Adams B, Wang J, Feng A, Marchi E, Roberts N, Wilcox R, Gutierrez M, Frosch Z, Sklarz T, Sethi T, Foss F, Beaven A, Haverkos B, Treitman R, Stevens P, Mishra A, Stuver R, Hampel P, Brammer J. Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort. Blood 2024, 144: 982-982. DOI: 10.1182/blood-2024-194242.Peer-Reviewed Original ResearchT-cell prolymphocytic leukemiaProgression-free survivalOverall survivalMedian OSFrontline treatmentT-PLL patientsTherapeutic outcomesMedian follow-up timeT-cell prolymphocytic leukemia cellsResponse rateCompared to CD4Multi-center seriesVenetoclax-based regimensSecond-line treatmentKaplan-Meier methodFollow-up timeSubgroup survival analysisCox proportional hazards modelsComprehensive clinical dataMulti-center studyProportional hazards modelFrontline therapyNodal involvementResponding patientsT-PLLTopical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances.
Del Rosso J, Bunick C, Kircik L, Bhatia N. Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances. Journal Of Drugs In Dermatology 2024, 23: 438-445. PMID: 38834223, DOI: 10.36849/jdd.8318.Peer-Reviewed Original ResearchConceptsAcne vulgarisTopical clindamycinTreatment of acne vulgarisManagement of acne vulgarisEmergence of antibiotic-resistant bacteriaAntibiotic-resistant bacteriaTopical agentsAnti-inflammatory propertiesTherapeutic advancesClindamycinClinical studiesTherapeutic outcomesClinical applicationAntimicrobial profileGram-positive bacteriaAnaerobic bacteriaMode of actionVulgarisMonotherapyPublished dataBacteriaTherapyAcneAntibioticsSex-specific outcomes in cancer therapy: the central role of hormones
Bakhshi P, Ho J, Zanganeh S. Sex-specific outcomes in cancer therapy: the central role of hormones. Frontiers In Medical Technology 2024, 6: 1320690. PMID: 38362126, PMCID: PMC10867131, DOI: 10.3389/fmedt.2024.1320690.Peer-Reviewed Original ResearchHormone replacement therapyHormone-sensitive cancersSex hormonesTreatment outcomesCancer therapyCancer progressionEstrogen receptor-negativeEstrogen receptor-positiveAndrogen receptor signalingSex-specific outcomesInhibit cancer progressionReceptor-negativeReceptor-positiveAromatase inhibitorsReplacement therapyTreatment responseAnti-androgenHormone levelsTherapeutic outcomesPersonalized therapyHormonal profileReceptor signalingTherapyCancer treatmentCancerTherapist and treatment credibility in treatment outcomes: A systematic review and meta-analysis of clients’ perceptions in individual and face-to-face psychotherapies
Kumpasoğlu G, Campbell C, Saunders R, Fonagy P. Therapist and treatment credibility in treatment outcomes: A systematic review and meta-analysis of clients’ perceptions in individual and face-to-face psychotherapies. Psychotherapy Research 2024, 35: 139-154. PMID: 38176020, PMCID: PMC11771474, DOI: 10.1080/10503307.2023.2298000.Peer-Reviewed Original ResearchTreatment outcomesTreatment credibilityEffective Public Health Practice Project toolSystematic reviewEMBASE online databasesEnglish peer-reviewed journalsBetter therapeutic outcomesPeer-reviewed journalsEligible studiesInclusion criteriaStudy qualityTherapist-delivered interventionsTherapy phaseClients' perceptionsTherapeutic outcomesSmall sample sizeStrong associationFace psychotherapyOutcomesTherapist credibilityPositive associationTreatmentOnline databasesAssociationReviewAmygdala response to emotional faces following acute administration of psilocybin in healthy individuals
Armand S, Larsen K, Madsen M, Ozenne B, Preller K, Knudsen G, Stenbæk D, Fisher P. Amygdala response to emotional faces following acute administration of psilocybin in healthy individuals. Neuroscience Applied 2024, 3: 103934. DOI: 10.1016/j.nsa.2023.103934.Peer-Reviewed Original ResearchPlasma psilocin levelsFunctional magnetic resonance imagingAmygdala reactivityHealthy individualsAmygdala responseMagnetic resonance imagingAcute administrationDrug intensityAcute exposureTherapeutic outcomesResonance imagingSignificant associationBrain regionsPsychedelic psilocybinPsilocybinBaselineFuture studiesSignificant changesExposureFearful facesEmotion processingResponseIndividualsAdministration
2023
Evolution of predictive risk factor analysis for chemotherapy-related toxicity
Hertz D, Lustberg M, Sonis S. Evolution of predictive risk factor analysis for chemotherapy-related toxicity. Supportive Care In Cancer 2023, 31: 601. PMID: 37773300, DOI: 10.1007/s00520-023-08074-x.Peer-Reviewed Original ResearchConceptsTreatment-related toxicityBiomarker discovery approachClinical practiceTaxane-induced peripheral neuropathyChemotherapy-related toxicitySame treatment regimenMaximum treatment benefitRisk factor analysisPrecision oncology treatmentsToxicity riskPeripheral neuropathyTreatment regimenSimilar patientsToxicity predictorsTreatment benefitPharmacogenetic predictorsOncology treatmentSide effectsTherapeutic outcomesCancer treatmentMinimal toxicityIntegrated biomarkersGermline genomicsBiomarker sciencePatientsBiomarkers and biosensors for early cancer diagnosis, monitoring and prognosis
Wahab M, Palaniyandi T, Ravi M, viswanathan S, Baskar G, Surendran H, Gangadharan S, Rajendran B. Biomarkers and biosensors for early cancer diagnosis, monitoring and prognosis. Pathology - Research And Practice 2023, 250: 154812. PMID: 37741139, DOI: 10.1016/j.prp.2023.154812.Peer-Reviewed Original ResearchEarly cancer diagnosisBiosensorEarly cancer detectionCancer biomarkersChip modelSuch biomarkersEngineering technologyBiological samplesCancer typesRecent advancementsEarly detectionNucleic acidsEarly diagnostic markerCancer detectionDevelopment of technologyGlobal socioeconomic impactTumor cell DNAProstate cancerMajor challengeBiomedical engineering technologyTherapeutic outcomesDetectionDiagnostic markerTechnologyParticular cancer typesAdapting psychedelic medicine for headache and chronic pain disorders
Schindler E, Hendricks P. Adapting psychedelic medicine for headache and chronic pain disorders. Expert Review Of Neurotherapeutics 2023, 23: 867-882. PMID: 37652000, DOI: 10.1080/14737175.2023.2246655.Peer-Reviewed Original ResearchConceptsChronic pain disordersPain disordersHeadache disordersChronic pain patientsRecent case reportsDifferent treatment paradigmsPsychedelic medicineSubstance use disordersMechanism of actionPain patientsChronic painCase reportClinical trialsTreatment paradigmTreatment outcomesTherapeutic effectLarge dosesUse disordersAdjunctive psychotherapyTherapeutic outcomesHeadacheBeneficial effectsSubjective effectsBranches of medicineDisordersClassification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
Stahl M, Bewersdorf J, Xie Z, Porta M, Komrokji R, Xu M, Abdel-Wahab O, Taylor J, Steensma D, Starczynowski D, Sekeres M, Sanz G, Sallman D, Roboz G, Platzbecker U, Patnaik M, Padron E, Odenike O, Nimer S, Nazha A, Majeti R, Loghavi S, Little R, List A, Kim T, Hourigan C, Hasserjian R, Halene S, Griffiths E, Gore S, Greenberg P, Figueroa M, Fenaux P, Efficace F, DeZern A, Daver N, Churpek J, Carraway H, Buckstein R, Brunner A, Boultwood J, Borate U, Bejar R, Bennett J, Wei A, Santini V, Savona M, Zeidan A. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews 2023, 62: 101128. PMID: 37704469, DOI: 10.1016/j.blre.2023.101128.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInternational consensus classificationResponse assessmentWorld Health Organization classificationPatient-centered careRisk assessment toolClinical outcomesRisk stratificationOrganization classificationCentered careTherapeutic benefitTherapeutic outcomesConsensus classificationResponse criteriaInternational ConsortiumNeoplasmsLife assessmentAssessment toolOutcomesReportAssessmentPrognosticationCareImaging the transmembrane pH gradient in gliomas
Mishra S, Mihailović J, Hyder F, Coman D. Imaging the transmembrane pH gradient in gliomas. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/3928.Peer-Reviewed Original ResearchAssess tumor aggressivenessMonitoring treatment efficacyTransmembrane pH gradientTumor responseTumor microenvironmentTumor aggressivenessRG2 tumorsLocal drug deliveryExtracellular acidosisTherapeutic outcomesTumorTreatment efficacyNormal tissuesBrain tumorsIntracellular pHExtracellular pHFunction biomarkersPositive therapeutic outcomesDrug deliveryIntracellular milieuBrainAcidosisGliomaUnderlying Hippocampal Mechanism of Posttraumatic Stress Disorder Treatment Outcome: Evidence From Two Clinical Trials
Zilcha-Mano S, Duek O, Suarez-Jimenez B, Zhu X, Lazarov A, Helpman L, Korem N, Malka M, Harpaz-Rotem I, Neria Y. Underlying Hippocampal Mechanism of Posttraumatic Stress Disorder Treatment Outcome: Evidence From Two Clinical Trials. Biological Psychiatry Global Open Science 2023, 3: 867-874. PMID: 37881552, PMCID: PMC10593870, DOI: 10.1016/j.bpsgos.2023.01.005.Peer-Reviewed Original ResearchPosttraumatic stress disorderRight hippocampal volumeHippocampal volumeSymptom reductionPosttreatment magnetic resonance imagingPosttraumatic stress disorder treatment outcomeLarger hippocampal volumesDisorder treatment outcomesPTSD symptom reductionMagnetic resonance imagingGreater PTSD symptom reductionBetter prognosisClinical trialsTreatment outcomesDepressive symptomsTherapeutic outcomesPTSD treatmentResonance imagingTreatment studiesClinical targetsStress disorderPTSD symptomsSmall sample sizeHippocampal mechanismsTreatment
2022
Novel pathophysiological insights in autoimmune myasthenia gravis
Masi G, O’Connor K. Novel pathophysiological insights in autoimmune myasthenia gravis. Current Opinion In Neurology 2022, 35: 586-596. PMID: 35942663, PMCID: PMC9458626, DOI: 10.1097/wco.0000000000001088.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAutoimmune myasthenia gravisMyasthenia gravisMG patientsClinical responseMuscle-specific tyrosine kinaseSpecific therapeutic strategiesNovel pathophysiological insightsMG pathologyMG subtypesAutoantibody repertoireTreatment optionsCancer immunotherapyPredictive biomarkersSuch therapyImmunological heterogeneityPathophysiological insightsMG phenotypeTherapeutic strategiesClinical observationsTherapeutic outcomesAcetylcholine receptorsDisease subtypesTherapeutic perspectivesSubtypesDevelopment of assaysDevelopment of an Accessible Gene Expression Bioinformatics Pipeline to Study Driver Mutations of Colorectal Cancer
van den Driest L, Johnson CH, Rattray NJW, Rattray Z. Development of an Accessible Gene Expression Bioinformatics Pipeline to Study Driver Mutations of Colorectal Cancer. Alternatives To Laboratory Animals 2022, 50: 282-292. PMID: 35765262, DOI: 10.1177/02611929221107546.Peer-Reviewed Original ResearchConceptsColorectal cancerBioinformatics toolsExpression patternsKirsten rat sarcoma viral oncogene homologueNext-generation sequencing technologiesDifferential expression patternsCancer-related mortalityGenetic alterationsAdenomatous polyposis coliEffector proteinsMutational driversPrognostic significancePrognostic valueSequencing technologiesBioinformatics pipelinePatient prognosisGenetic dataB-RafColorectal tumorsNovel biomarkersColon cancerTherapeutic outcomesFrequency of mutationsAnatomical locationOncogene homologue
2021
Stimulus‐Responsive Nanoparticles for Therapeutic Stabilization of Atherosclerosis
Mehta S, Ahamad N, Dewani M, Bhardwaj P, Banerjee R. Stimulus‐Responsive Nanoparticles for Therapeutic Stabilization of Atherosclerosis. 2021, 181-215. DOI: 10.1002/9783527832095.ch7.ChaptersAtherosclerosis treatmentPlaque sitesNon-selective accumulationElevated enzyme levelsOff-target toxicityTherapeutic stabilizationFree drug deliveryCardiovascular complicationsBlood flowAtherosclerosisTherapeutic outcomesFirst lineOxidative stressArtery wallEnzyme levelsExogenous strategiesProgressive accumulationApparent toxicityCellular debrisTreatmentEndogenous triggersStimuli-responsive nanoparticle systemToxicitySuccessful deliveryDrug-loaded nanoparticlesCachexia and bladder cancer: clinical impact and management
Lokeshwar SD, Press BH, Nie J, Klaassen Z, Kenney PA, Leapman MS. Cachexia and bladder cancer: clinical impact and management. Current Opinion In Supportive And Palliative Care 2021, 15: 260-265. PMID: 34698663, DOI: 10.1097/spc.0000000000000580.Peer-Reviewed Original ResearchConceptsRadical cystectomyBladder cancerPharmacological agentsManagement of cachexiaNovel pharmaceutical agentsPostoperative complicationsWorse survivalMultidisciplinary managementClinical outcomesHypercatabolic statePalliative carePoor outcomeClinical trialsNutritional supplementationBCa patientsClinical impactPhysical therapyCachexiaRadiation therapyHuman studiesPatientsTherapeutic outcomesNutritional deficienciesNutritional supplementsTumor microenvironmentThe Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic
Izadmehr S, Lundon D, Mohamed N, Katims A, Patel V, Eilender B, Mehrazin R, Badani K, Sfakianos J, Tsao C, Wiklund P, Oh W, Cordon-Cardo C, Tewari A, Galsky M, Kyprianou N. The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. Frontiers In Oncology 2021, 11: 734963. PMID: 34646777, PMCID: PMC8504458, DOI: 10.3389/fonc.2021.734963.Peer-Reviewed Original ResearchGenitourinary cancersCancer patientsManagement of genitourinary cancersClinical management of patientsManagement of prostateManagement of patientsGU cancer patientsClinically relevant changesIncidence of infectionSARS-CoV-2 infectionConsequences of SARS-CoV-2 infectionPenile cancerSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Poor outcomeTherapeutic modalitiesClinical managementFatal outcomeRespiratory syndrome coronavirus 2Disease progressionTherapeutic outcomesCoronavirus disease-2019PatientsSyndrome coronavirus 2Secondary impacts of COVID-19
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply